Thrombolytic agents for arterial and venous thromboses in neonates

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective is to assess the effectiveness and safety of thrombolytic agents (Streptokinase, Urokinase, rTPA) for the treatment of clinically manifest arterial or venous thrombosis in newborn infants. We aim to establish an effective and safe dosage or treatment regime. In separate comparisons, we will compare thrombolytic agents with either no treatment, heparin, or surgery, each used as primary treatment. Secondary objectives are to conduct subgroup analyses within each comparison, in which we will assess treatment effects on arterial thromboses, on venous thromboses; and according to the specific thrombolytic agent tested: streptokinase, urokinase, rTPA. We aim to specifically test the following hypotheses: Thrombolytic agents in symptomatic arterial or venous thrombosis are effective in preventing complications including limb or organ ischaemia.